Skip to main content

Table 2 Prognostic factors for overall survival

From: Outcome of therapy-related myeloid neoplasms treated with azacitidine

  Patients
(n)
Number of responders § Median OS
(months)
p
Age
≤ 65 years 24 10 21.9 0.85
> 65 years 26 10 24.5  
Primary Malignancy
Hematological 27 12 11.67 0.83
Solid 23 8 17.97  
azacitidine dose
75 mg/smq/7 days 36 12 16.7 0.31
100 mg/day 10 days 4 3 14.2  
100 mg/day 5 or 7 days 10 5 16.2  
WHO diagnosis
RCMD 12 9 30.9  
RAEB 1/2 22 7 16.8 0.02
AML 16 4 8.5  
Karyotype
Normal 8 8 27.7  
Single or double abnormality 9 3 11.6 0.66*
Complex 20 9 16.2  
Chromosome 7 abnormalities
Yes 14 8 11.63 0.72
No 33 12 17.96  
Transfusion dependence
Yes 26 10 11.6 0.38
No 24 10 21.9  
Previous Treatment
No pre-treatment 40 17 27.7 0.0001
ESA 4 2 16.2  
Hydroxyurea 2 1 9.5  
Conventional Chemotherapy 4 0 5.4  
HCT-CI #
0–2 5 0 8.8  
3 19 6 8.5 0.2
4 6 4 53.7  
>5 9 4 16.2  
  1. * The difference in overall survival between normal and aberrant karyotype was however statistically significant restricting the analysis to t-AML patients (Figure 3A).
  2. § Number of patients achieving CR, PR or HI; # HCT-CI data were available for 39 patients.